



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Tsvee LAPIDOT

Art Unit: 1632

Application No.: 09/744,654

Conf. No. 2645

Examiner: A. M. S. Wehbe

Filed: January 29, 2001

Washington, D.C.

For: HEMATOPOIETIC CELL COMPOSITION FOR USE IN...

Atty.'s Docket: LAPIDOT2

Date: September 13, 2004

THE HONORABLE COMMISSIONER FOR PATENTS
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop: Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

Transmitted herewith is a ☒ Amendment ☐ _____
in the above-identified application.

☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

☒ No additional fee is required.

☐ The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS	RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
TOTAL	* 8	MINUS	** 52	0	x 9	\$		x 18	\$
INDEP.	* 2	MINUS	*** 9	0	x 43	\$		x 86	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ 145	\$		+ 290	\$
					ADDITIONAL FEE TOTAL	\$	OR	TOTAL	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

☐ First - \$ 55.00

☐ Second - \$ 210.00

☐ Third - \$ 475.00

☐ Fourth - \$ 740.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

☐ First - \$ 110.00

☐ Second - \$ 420.00

☐ Third - \$ 950.00

☐ Fourth - \$ 1480.00

Month After Time Period Set

☐ Less fees (\$ _____) already paid for ____ month(s) extension of time on _____.

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.

☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.

☐ A check in the amount of \$ _____ is attached (check no. _____).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 

Allen C. Yun

Registration No.: 37,971

Facsimile: (202) 737-3528
Telephone: (202) 628-5197



1632
Jfw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: LAPIDOT=2

In re Application of:)	Art Unit: 1632
)	
Tsvee LAPIDOT et al)	Examiner: A. WEHBE
)	
Appln. No.: 09/744,654)	Washington, D.C.
)	
Date Filed: January 29, 2001)	Confirmation No. 2645
)	
For: HEMATOPOIETIC CELL)	September 13, 2004
COMPOSITION FOR USE IN...)	

AMENDMENT

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **Mail Stop Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

In response to the Office Action of June 15, 2004,
please amend as follows:

Amendments to the Claims are reflected in the listing of claims
which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.

Attachments include a copy of Kollet et al. (2003) publication
attached following page 7 of this paper.